Efficacy and Safety of Desmopressin Add-On Therapy for Men with Persistent Nocturia on α-Blocker Monotherapy for Lower Urinary Tract Symptoms: A Randomized, Double-Blind, Placebo Controlled Study.
We investigated the efficacy and safety of desmopressin add-on therapy for men with persistent nocturia on α-blocker for lower urinary tract symptoms in this placebo controlled study.



The study included men 40 to 65 years old with lower urinary tract symptoms and persistent nocturia despite α-blocker therapy for at least 8 weeks. Patients were randomized to once daily placebo or desmopressin 0.2 mg for 8 weeks. The primary end point was to assess changes in the mean number of nocturia episodes from baseline to the final assessment. Other secondary end points and adverse events were evaluated.



A total of 86 patients were randomized to treatment, including placebo in 39 and desmopressin 0.2 mg in 47. Baseline characteristics were similar in the 2 groups. The desmopressin add-on group was significantly superior to placebo in terms of the change from baseline in the mean number of nocturia episodes (-1.13 ± 0.92 vs -0.68 ± 0.79, p = 0.034), the changes in nocturnal urine volume (p <0.001), total I-PSS (International Prostate Symptom Score) (p = 0.041), the nocturnal polyuria index (p = 0.001) and ICIQ-N (International Consultation on Incontinence Questionnaire-Nocturia) (p = 0.001), and the willingness to continue (p = 0.025). The incidence of adverse events in the desmopressin add-on group was similar to that in the placebo group. Most adverse events were mild.



Desmopressin add-on therapy in men 40 to 65 years old with persistent nocturia on α-blocker monotherapy for lower urinary tract symptoms is effective and well tolerated.
Department of Urology, Bucheon St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea.
Joon Chul
JC
Kim
Department of Urology, Bucheon St. Mary's Hospital, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea.
Kang Jun
KJ
Cho
Department of Urology, College of Medicine, Korea University, Seoul, Republic of Korea.
Jeong Gu
JG
Lee
Department of Urology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Seoul, Republic of Korea.
Ju Tae
JT
Seo
Department of Urology, Daegu Catholic University College of Medicine, Daegu, Republic of Korea.
Duk Yoon
DY
Kim
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Seung-June
SJ
Oh
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Kyu-Sung
KS
Lee
Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Myung-Soo
MS
Choo
Department of Urology, Pusan National University School of Medicine, Busan, Republic of Korea. Electronic address: toohotman@hanmail.net.
Jeong Zoo
JZ
Lee
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D050034:Antidiuretic Agents / Q000627:therapeutic use*; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D053158:Nocturia / Q000188:drug therapy*; D010919:Placebos; D011141:Polyuria / Q000188:drug therapy*; D011788:Quality of Life; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D050034:Antidiuretic Agents; D010919:Placebos; D003894:Deamino Arginine Vasopressin
adrenergic alpha-antagonists; deamino arginine vasopressin; lower urinary tract symptoms; nocturia; urinary bladder